Celgene (NASDAQ:CELG) was downgraded by equities research analysts at Vetr from a “strong-buy” rating to a “buy” rating in a report released on Monday, December 18th. They presently have a $121.72 price objective on the biopharmaceutical company’s stock. Vetr‘s target price would indicate a potential upside of 14.83% from the stock’s current price.
Several other equities analysts have also recently commented on the company. Cantor Fitzgerald restated a “buy” rating on shares of Celgene in a research report on Tuesday, August 22nd. BTIG Research restated a “neutral” rating on shares of Celgene in a research report on Tuesday, September 5th. Cowen restated a “buy” rating and set a $150.00 target price on shares of Celgene in a research report on Tuesday, September 12th. Bank of America restated a “buy” rating on shares of Celgene in a research report on Wednesday, September 13th. Finally, Royal Bank of Canada initiated coverage on Celgene in a research report on Thursday, September 14th. They set a “top pick” rating and a $176.00 target price for the company. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $131.18.
Celgene (NASDAQ CELG) traded up $1.42 during trading hours on Monday, hitting $106.00. The company had a trading volume of 8,748,713 shares, compared to its average volume of 6,330,000. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene has a 12 month low of $94.55 and a 12 month high of $147.17. The company has a market cap of $83,460.00, a price-to-earnings ratio of 25.00, a price-to-earnings-growth ratio of 0.67 and a beta of 1.77.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the previous year, the company posted $1.58 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. sell-side analysts predict that Celgene will post 6.69 EPS for the current fiscal year.
A number of hedge funds have recently modified their holdings of the stock. Arcadia Investment Management Corp MI raised its position in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares during the last quarter. Thompson Davis & CO. Inc. raised its position in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares during the last quarter. Robecosam AG bought a new position in Celgene during the 3rd quarter valued at approximately $114,000. Capital Bank & Trust Co raised its position in Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 517 shares during the last quarter. Finally, Guidant Wealth Advisors bought a new position in shares of Celgene in the 3rd quarter worth approximately $119,000. Institutional investors own 79.74% of the company’s stock.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.